At its July 2024 meeting, EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) elected Ulla Wändel Liminga as its new Chair for a three-year mandate starting in September 2024.
A pharmacist by training, with a doctoral thesis in medical sciences from Uppsala University in Sweden, Ulla Wändel Liminga is Scientific Director of Pharmacovigilance at the Swedish Medical Products Agency.
She is a specialist in pharmacology, toxicology and pharmacovigilance and has extensive experience in the EU’s regulatory system from her work at the Swedish Medical Products Agency and, early on in her career, at EMA. Dr Wändel Liminga has been one of the Swedish PRAC delegates since the committee was established in 2012…
